Facial nodules and compounded tirzepatide

A 2026 case report described persistent facial nodules in one woman after cosmetic filler and botulinum toxin injections while she was using compounded tirzepatide. A later exchange in JAAD Case Reports debated whether inflammation or an indolent infection better explains the pattern. The authors favored inflammation. No biopsy was performed, and there was no tissue culture or aspirate testing. The cause remains unresolved. The case cannot establish that tirzepatide caused the nodules^[1][2][3]. The product was compounded, not an FDA-approved Mounjaro or Zepbound product, so the observation should not be generalized to approved tirzepatide.

What happened in the case

The report concerned a 66-year-old woman who developed nodules at sites treated with two fillers, hyaluronic acid and calcium hydroxyapatite, as well as incobotulinumtoxin A. She had undergone similar procedures before starting compounded tirzepatide without developing nodules. One month after beginning the compounded product, she received more cosmetic injections. Several weeks later, a large cheek nodule and a smaller nodule near the cheekbone appeared. More nodules later developed at other treated facial sites^[1].

The lesions did not improve after intralesional triamcinolone or hyaluronidase. Two 30-day courses of doxycycline also failed. After compounded tirzepatide was stopped, existing nodules did not disappear immediately, but the authors reported that no new nodules formed. Isotretinoin was then started, and the lesions resolved within one month^[1]. These treatment details describe one clinical course. They are not a treatment protocol for facial nodules.

The patient later restarted compounded tirzepatide while continuing isotretinoin. No nodules appeared after further filler injections at the lower tirzepatide dose. After the compounded dose was increased in steps, two small upper-lip nodules formed at earlier filler sites four weeks later^[1]. This stop-and-restart pattern makes the timing more notable, but several things changed together. Isotretinoin remained in use, filler was injected again, and the contents of the compounded product were unknown.

Why the authors favored inflammation

The follow-up letter identified by PMID 42598502 was the original authors' response to an infectious explanation. They emphasized that the patient did not improve after two courses of doxycycline and did improve after isotretinoin. They also argued that repeated nodules at distant facial injection sites, despite procedures by different practitioners, were less consistent with one shared contaminant. In their view, the absence of new nodules after stopping the compounded product and recurrence after restarting it supported an inflammatory pathway^[2].

That interpretation is plausible, but it remains an interpretation. The response confirms that a biopsy was not performed because the nodules were in cosmetically sensitive facial areas and the patient declined the procedure^[2]. That gap matters. Without tissue, the clinicians could not look for the cellular pattern expected in a sterile inflammatory reaction. They also could not culture tissue or use other laboratory methods to look for organisms.

Why infection and biofilm remain open

A separate correspondence argued that slow infections can resemble sterile filler reactions. It specifically raised biofilm-associated infection, nontuberculous mycobacteria, and low-grade staphylococcal infection as possibilities after dermal filler or other injectable procedures. A biofilm is a community of microbes attached to a surface and protected by a matrix, which can make infection persistent and difficult to detect. The letter said that the absence of biopsy, culture, or aspirate analysis meant infection had not been excluded with confidence^[3].

Treatment response does not settle that dispute. The critical letter noted that doxycycline acts against microbes and can also affect inflammation and biofilms. Isotretinoin can alter immune signaling. The original authors answered that there had been no improvement with doxycycline, contrary to the critic's reading, and regarded the isotretinoin response as evidence for inflammation^[2][3]. Both sides agree on the central limitation: microbiological and histological confirmation was absent.

Why the compounded product matters

The case involved compounded tirzepatide throughout. The original report lists unknown ingredients in that preparation as a limitation and says the available evidence cannot separate tirzepatide itself from compounded ingredients or another cause^[1]. FDA states that compounded drugs are not FDA approved. The agency does not review their safety and effectiveness or verify their quality before marketing. Poor compounding practices can lead to contamination or incorrect amounts of active ingredient^[4]. That general warning does not show that this patient's vial was contaminated. It explains why product identity and quality remain part of the uncertainty.

FDA-approved tirzepatide products have reviewed formulations and labels, backed by manufacturing controls. A reaction reported during use of an unidentified compounded preparation cannot establish the same risk for Mounjaro or Zepbound^[4]. Readers looking for the broader evidence can use our tirzepatide safety overview and our United States tirzepatide regulation page.

What we do not yet know

We do not know whether the nodules were caused by sterile inflammation or infection. Filler-related biology, an ingredient in the compounded product, tirzepatide, or several factors together could also explain the course. Nor do we know how often a similar sequence occurs. A single selected case provides no denominator or untreated comparison, so it cannot estimate risk. The response letter strengthens the authors' explanation of the timeline, but it does not add laboratory confirmation or another patient^[1][2].

Future reports would be more informative if they documented the exact compounded formulation and its source. When clinically acceptable, investigators could obtain tissue or aspirate for histology and microbiological testing, including tests for bacteria, fungi, and mycobacteria. Repeated cases with those data could help distinguish a medicine-related inflammatory signal from known complications of cosmetic injections. For now, persistent or recurrent facial nodules after an injectable procedure warrant assessment by a qualified clinician. This report does not justify self-treatment or changing a prescription without the clinician managing it.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.